Ultrasound and photoacoustic imaging to monitor treatment response in triple negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether a new imaging approach using ultrasound and photoacoustic imaging can detect early whether the tumor is responding to standard immunotherapy and chemotherapy before surgery. It aims to improve treatment monitoring for patients with stage II-III triple negative breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage II or stage III triple negative breast cancer.
- You are eligible to receive the standard KEYNOTE-522 treatment (immunotherapy plus chemotherapy).
- Your cancer has not spread to other parts of the body.
- If you could become pregnant, you must have a negative pregnancy test before starting and use an approved birth control method during the trial.
- You must be able to give informed consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
This trial tests whether using blood tests and imaging during chemotherapy and immunotherapy can help guide treatment for early-stage triple-negative breast cancer. It aims to improve outcomes by adjusting treatment based on how the cancer responds.
This study uses a special light-based imaging scan to learn more about breast masses and how tumors may respond to chemotherapy before surgery. The scan is meant to help doctors better characterize tumors and potentially track treatment response.
This study uses special ultrasound imaging (and may use MRI results) to look for early signs of how locally advanced breast cancer responds to chemotherapy, with or without radiation. If the imaging changes early, it could help doctors adjust treatment sooner.
This trial tests if using MRI scans can safely reduce the amount of chemotherapy and immunotherapy needed before surgery for triple-negative breast cancer. All patients will receive the standard KEYNOTE-522 regimen, but the treatment may be tailored based on MRI results.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
Hear when a new Anatomic Stage II Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.